Management of Hematologic Malignancies: Special Considerations in Pregnant Women

Drugs. 2015 Oct;75(15):1725-38. doi: 10.1007/s40265-015-0464-0.

Abstract

The diagnosis and management of hematologic malignancy during pregnancy is a significant challenge. This is due to both medical and ethical considerations regarding when and how to treat this special sub-group of patients. Recurring uncertainties remain around appropriate imaging techniques, timing and dosage of chemotherapy, and timing of delivery. In this article we examine and summarize current literature in this field to assist physicians in their understanding and management of this patient group. Special attention has been given to diagnostic and staging procedures, risks associated with chemotherapy at different stages of gestation, and chemotherapy-dose adaption during pregnancy. In addition, recommended guidelines for management of lymphoma, leukemia, and planning delivery are discussed. A multidisciplinary team approach is critical for patient care, as is shared decision making with the patient and family.

Publication types

  • Review

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Disease Management
  • Female
  • Hematologic Neoplasms / drug therapy*
  • Humans
  • Pregnancy
  • Pregnancy Complications, Neoplastic / drug therapy*

Substances

  • Antineoplastic Agents